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Abstract
Background: The objective of this study was to analyze factors influencing the risk and timing of
Alzheimer's disease (AD) in central Norway. The APOE ε4 allele is the only consistently identified
risk factor for late onset Alzheimer's disease (LOAD). We have described the allele frequencies of
the apolipoprotein E gene (APOE) in a large population of patients with AD compared to the
frequencies in a cognitively-normal control group, and estimated the effect of the APOE ε4 allele on
the risk and the age at onset of AD in this population.
Methods: 376 patients diagnosed with AD and 561 cognitively-normal control individuals with no
known first degree relatives with dementia were genotyped for the APOE alleles. Allele frequencies
and genotypes in patients and control individuals were compared. Odds Ratio for developing AD
in different genotypes was calculated.
Results: Odds Ratio (OR) for developing AD was significantly increased in carriers of the APOE ε4
allele compared to individuals with the APOE ε3/ε3 genotype. Individuals carrying APOE ε4/ε4 had
OR of 12.9 for developing AD, while carriers of APOE ε2/ε4 and APOE ε3/ε4 had OR of 3.2 and 4.2
respectively. The effect of the APOE ε4 allele was weaker with increasing age. Carrying the APOE
ε2 allele showed no significant protective effect against AD and did not influence age at onset of
the disease. Onset in LOAD patients was significantly reduced in a dose dependent manner from
78.4 years in patients without the APOE ε4 allele, to 75.3 in carriers of one APOE ε4 allele and 72.9
in carriers of two APOE ε4 alleles. Age at onset in early onset AD (EOAD) was not influenced by
APOE ε4 alleles.
Conclusion: APOE ε4 is a very strong risk factor for AD in the population of central Norway, and
lowers age at onset of LOAD significantly.
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Apolipoprotein E (APOE) is a multifunctional circulating
lipoprotein consisting of 299 amino acids, synthesized in
various organs, including liver, spleen, kidney and brain
[1]. Three common isoforms of the protein are identified
as ApoE 2, ApoE 3 and ApoE 4. These isoforms are coded
for by three different alleles (denoted by a specific combi-
nation of two coding SNPs), located within the APOE
gene on chromosome 19q13.2. APOE ε2, APOE ε3 and
APOE ε4 account for more than 99% of the variation of
APOE [2]. The frequencies of these three APOE alleles are
highly variable in different populations [3-5]. Globally,
APOE ε3 is the most frequently occurring allele, constitut-
ing 60–90% of the allelic variation. APOE ε2 constitutes
0–20% and APOE ε4 10–20% of allelic variation [5,6].
APOE ε3 and APOE ε4 are also found to be inversely cor-
related in European populations with the APOE ε4 allele
found more frequently in populations in northern Europe
than in southern Europe [4].
Carrying the APOE ε4 allele is a risk factor for early onset
Alzheimer's disease (AD), and is the only consistently
identified risk factor for late-onset Alzheimer's disease
(LOAD) [7-11]. APOE ε4 acts in a dose-dependant man-
ner: carriers of two APOE ε4 alleles have a higher risk and
earlier onset of AD than heterozygous subjects [12-14].
Only a few studies have examined the APOE allele fre-
quencies in AD patients in Scandinavia [15-19]. In the
present study we describe APOE genotypes and allele fre-
quencies in AD patients and a cohort of controls from cen-
tral Norway where the population is comparatively
genetically homogeneous.
Methods
The clinical material consisted of 376 patients diagnosed
with probable or possible AD and 561 cognitively-normal
controls, all ethnic Norwegians. The patients were neuro-
logical and geriatric patients recruited from the University
Hospital of Trondheim, the district hospital in Namsos
and patients from nursing homes in central Norway. The
inclusion period lasted from May 2003 until September
2006. Patients or suitable proxies were asked about case
history, including a family history of dementia. Neurolog-
ical examination was completed by one neurologist (SBS)
in all patients and included the Mini-Mental State Exami-
nation (MMSE) [20] and Clock Drawing Test [21]. Blood
screening was performed, and secondary causes of demen-
tia were excluded. Additional tests including EEG, lumbar
puncture or an olfactory test were performed in subgroups
[22]. Blood samples for DNA extraction and genetic test-
ing were obtained from all patients and control subjects.
The guidelines given in the International Classification of
Diseases tenth revision (ICD-10) were applied for diag-
nosing dementia. Patients diagnosed with Alzheimer's
disease met the Criteria for probable or possible AD from
the National Institute of Neurological and Communica-
tive Disorders and Stroke and the Alzheimer's disease and
Related Disorders Association (NINCDS-ADRDA) [23].
Healthy spouses and members of societies for retired peo-
ple in central Norway were recruited for the cognitively-
normal control group. Only ethnic Norwegians without
known dementia in first degree relatives were included.
Both patients and controls were asked for place of birth,
place of residence during childhood, number of years of
education, and former occupation. Informed consent was
obtained from patients or suitable proxies and from all
control subjects. The study was approved by the Regional
Committee for Medical Research Ethics in central Norway.
Genotyping
Overall APOE genotype was determined by the combina-
tions of genotypes at two single nucleotide polymor-
phisms (SNPs), rs7412 and rs429358. Genotyping was
performed using predesigned Taqman Assays on the
Applied Biosystems 7900 HT Fast Real Time PCR system,
and genotype calls were made using the SDS v2.2 software
(Applied Biosystems). Any sample in which the Taqman
assays gave inconclusive allele calls was re-genotyped
using a restriction fragment length polymorphism (RFLP)
method [24]. Deviation from Hardy Weinberg Equilib-
rium (HWE) was calculated for the APOE locus, and both
cases (p = 0.86) and controls (p = 0.36) were found to be
in HWE.
Statistical analyses
Data analysis was chiefly performed with the SPSS, ver-
sion 13. Categorical variables were compared using Pear-
son's chi-square test. Age at onset in different groups was
compared by Wilcoxon-Mann-Whitney's test. Odds ratios
(OR) were calculated for each genotype by binary logistic
regression, using the ε3/ε3 genotype as reference value.
Logistic regression was performed with exact conditional
maximum likelihood and median unbiased estimation in
LogXact. Two-sided p-value < 0.05 was considered signif-
icant. Standard deviation (SD) is given after mean value as
± SD.
Results
264 patients were diagnosed with probable AD (70.2%),
and 112 with possible AD (29.8%) according to the
NINCDS-ADRDA criteria. 263 were women (69.9%) and
113 were men (30.1%). 213 of the patients had first
degree relatives with dementia (56.6%), and 149 (39.6%)
had no known dementia in parents, siblings or children.
Family history was missing in 14 patients. Mean age at
inclusion for patients was 79.5 ± 8.2 years. The medianPage 2 of 7
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scores were missing in four patients.
The control group consisted of 561 subjects; 338 women
(60.2%) and 223 men (39.8%) (Table 1). Age at inclusion
for control individuals was 75.1 ± 7.3 years.
Allele frequencies and genotypes were calculated for
patients and controls, and for gender in each group (Table
1). The allele frequencies for men and women did not dif-
fer significantly either in controls or patients. The differ-
ences in allele frequencies in patients and controls were
significant. Allele frequencies were also calculated for
patients and control individuals according to age (Table
2). The frequency of the APOE ε4 allele in patients was
highest in those with age at onset 60–69 years (51.4%).
The oldest patients with onset ≥ 80 years had the lowest
proportion of the APOE ε4 allele (24.8%). While 64.1%
(n = 241) of the AD patients had one or two APOE ε4 alle-
les, only 26.4% (n = 148) of the control individuals car-
ried an APOE ε4 allele (p < 0.001). In patients with
dementia in first degree relatives 70.9% (n = 151) had one
or two APOE ε4 alleles, compared to 56.4% (n = 84) in
patients with no known history of dementia in first degree
relatives (p = 0.004).
The odds ratios (OR) for developing AD were calculated
for each APOE genotype, using ε3/ε3 as the reference
value (Table 3). These analyses were also carried out sep-
arately for patients with and without dementia in first
degree relatives. Significantly increased ORs were found in
all genotypes containing the APOE ε4 allele, both for the
group with dementia in first degree relatives and for those
with a negative family history. Odds Ratios for genotypes
containing an APOE ε4 allele were increased in the group
with a positive family history compared to those without
dementia in first degree relatives. Logistic regression with
the number of APOE ε2 and APOE ε4 alleles as covariates
showed no significant protective effect of either one APOE
ε2 allele (OR = 0.82; p = 0.32) or two APOE ε2 alleles (OR
= 0.73; p = 0.78). Logistic regression analysis with APOE
ε4 and age as covariates, showed a non-significant (p =
0.14) interaction, with a reduced effect of APOE ε4 in the
older patients.
Age at onset in patients with LOAD was significantly
reduced by the APOE ε4 allele in a dose dependent man-
ner, while it had no lowering effect in patients with onset
before 65 years (early onset AD, EOAD) (Table 4). In
LOAD patients without the APOE ε4 allele, mean age at
onset was 78.4 years, whereas those carrying one APOE ε4
allele had onset at 75.3 years (p = 0.005). For patients
with two APOE ε4 alleles, age at onset was further reduced
to 72.9 years. The difference in onset between carriers of
one and two APOE ε4 alleles was also significant (p =
0.002). Figure 1 shows onset in carriers of zero, one and
two APOE ε4 alleles. The presence of an APOE ε2 allele
had no significant effect on age at onset.
Table 1: Number of patients, age at inclusion, allele frequencies and genotypes in patients and controls
Number (Females/Males) Age at inclusion ± SD Allele frequencies (%) Genotypes
ε2 ε3 ε4 ε2/ε2 ε2/ε3 ε2/ε4 ε3/ε3 ε3/ε4 ε4/ε4
Alzheimer patients All 376 79.5 ± 8.2 7.3 53.1 39.6 0.3 7.4 6.6 28.2 42.3 15.2
F 263 80.3 ± 8.3 7.6 52.9 39.5 0.4 6.8 7.6 28.5 41.8 14.8
M 113 77.5 ± 7.6 6.6 53.5 39.8 0.0 8.8 4.4 27.4 43.4 15.9
Control persons All 561 75.1 ± 7.3 11.3 74.3 14.3 0.7 17.1 4.1 55.8 20.0 2.3
F 338 74.7 ± 7.1 10.9 74.4 14.3 0.6 16.6 4.1 55.9 21.0 1.8
M 223 75.7 ± 7.5 11.9 73.8 14.3 0.9 17.9 4.0 55.6 18.4 3.1
F = females
M = males
SD = Standard Deviation
Table 2: Allele frequencies by age
Age Number Allele frequencies(%)
ε2 ε3 ε4
< 60 24 8.3 52.1 39.6
Alzheimer patients 60–69 74 6.8 41.9 51.4
Age at onset 70–79 169 5.6 50.3 44.1
80–89 109 10.1 65.1 24.8
< 60 13 11.5 65.4 23.1
Control persons 60–69 109 11.0 72.9 16.1
Age at inclusion 70–79 293 10.6 76.1 13.3
80–89 135 12.6 72.2 15.2
90–99 11 18.2 77.3 4.5Page 3 of 7
(page number not for citation purposes)
BMC Neurology 2008, 8:9 http://www.biomedcentral.com/1471-2377/8/9Discussion
In this study we have described the APOE allele frequen-
cies in 376 AD patients and 561 healthy controls from
central Norway. Individuals carrying the APOE ε4 allele
had an increased OR for developing AD, both in
homozygous (12.9) and heterozygous individuals (4.2 for
ε3/ε4, 3.2 for ε2/ε4). Age at onset in LOAD patients was
significantly lowered by about three years for every APOE
ε4 allele the patient carried. The APOE ε2 allele did not
affect age at onset of AD and had no significant protective
effect on the risk of AD.
While smaller studies in this field have been published
from Norway, to our knowledge this is the first report of
APOE allele frequencies and APOE genotypes in a large
Norwegian AD population and the largest study on APOE
allele frequencies in AD patients from Scandinavia to
date. The study was performed in central Norway where
the migration of the population for several centuries has
been very modest. The population is therefore quite
genetically homogeneous. The frequency of APOE ε4 in
patients in the present study was similar to the result
obtained in a large meta-analysis of 5107 Caucasian AD
patients, where the APOE ε4 frequency was found to be
36.7% [25]. Age dependent variation in frequency of the
APOE ε4 allele in AD patients has been reported earlier
[26] and was also present in our study. In North America,
the estimated APOE ε4 allele frequency is 60% in the AD
population (15% ε4/4 and 40% with ε3/4 and < 5% with
ε2/4) [27]. In our study, we found that 64.1% of the
patients carried one or more APOE ε4 alleles (15.2% had
ε4/4, 42.3% had ε3/ε4 and 6.6% had ε2/4). Our findings
are thus in keeping with previous estimates in Caucasians.
The frequency of APOE ε4 in control individuals in the
present study was also similar to the frequency in a meta-
analysis of 6262 Caucasian control subjects from 1997
(13.7%) [25], though less than previously reported in a
Norwegian study (19.8%) [28]. However, the latter study
was conducted in 798 healthy blood donors aged < 40
Table 3: Odds Ratio for AD in all genotypes in patients with/without first degree relatives with dementia
Genotypes
ε2/ε2 ε2/ε3 ε2/ε4 ε3/ε3 ε3/ε4 ε4/ε4
Odds Ratio (376 AD patients; 561 control individuals) 0.7 0.9 3.2 1 4.2 12.9
CI 0.01–7.57 0.51–1.41 1.67–6.18 Ref 2.98–5.89 6.64–26.68
p value 1.00 0.62 < 0.001 < 0.001 < 0.001
Odds Ratio, AD patients with no family history of dementia (n = 149) 1.1* 0.7 2.8 1 2.9 8.1
CI 0.00–0.16 0.34–1.47 1.17–6.44 Ref 1.83–4.58 3.53–19.18
p value 1.00 0.47 0.021 < 0.001 < 0.000
Odds Ratio, AD patients with first degree relative with dementia (n = 213) 1.7 1.0 4.0 1 5.9 18.7
CI 0.03–17.27 0.47–1.89 1.79–8.86 Ref 3.88–9.15 8.97–41.40
p value 1.0 1.0 < 0.001 < 0.001 < 0.001
SD = Standard Deviation
CI = 95% confidence interval
Ref = Reference category
*The Median unbiased estimate is given, since the Maximum Likelihood estimate does not exist.
Table 4: Effect of the APOE ε4 allele on age at onset in LOAD and EOAD
Number of APOE ε4-alleles
0 1 2
EOAD. Age at onset ± SD, n 57.3 ± 4.0 14 57.3 ± 4.7 16 58.7 ± 2.6 10
LOAD. Age at onset ± SD, n 78.4 ± 5.8 121 75.3 ± 5.8a 168 72.9 ± 5.0b 47
SD = Standard deviation
n = number of patients
EOAD: Early onset Alzheimer's disease (onset < 65 years), no significant difference in onset between carriers of none, one and two APOE ε4 alleles.
LOAD: Late onset Alzheimer's disease (onset ≥ 65 years)
a: The difference between onset in LOAD (Late Onset AD) in carriers of none and one APOE ε4 allele was significant; p = 0.005.
b: The difference between onset in LOAD in carriers of one and two APOE ε4 alleles was significant; p = 0.002.Page 4 of 7
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with increasing age has been reported in healthy individ-
uals [29]. As our control population was significantly
younger than the AD patients, the APOE ε4 frequency
might actually be slightly increased compared to controls
of the same age as the patients. However, only control
individuals without known dementia in first degree rela-
tives were included in the present study, to increase the
probability of detecting genetic differences between AD
patients and control individuals. This selection may have
caused a lower proportion of the APOE ε4 allele than in
an unselected control population, as earlier findings sug-
gest that offspring of AD patients have a frequency of the
APOE ε4 allele that exceeds population estimates [30].
The frequency of patients reporting dementia in one or
more first degree relatives was high in this population
(56.6%). In most cases, both patients and next of kin were
asked about relatives with cognitive impairment, and this
may have increased the trend to report family members
with dementia. Other studies have also reported a high
occurrence of AD patients with dementia in first degree
relatives [19,31].
The present study confirmed that individuals carrying the
APOE ε4 allele are at increased risk for developing AD. The
ORs found in our study was close to those found previ-
ously in a large meta-analysis [25]. As the ORs calculated
in the present study may slightly overestimate the effect of
the APOE ε4 allele because of selection of the control
group, we performed analyses of the population of
patients with and without first degree relatives separately,
using the same 561 selected controls for both analyses.
This calculation showed increased ORs in the group con-
sisting of patients with dementia in first degree relatives
compared to the group without a known family history of
dementia. The true estimate of OR is in between these esti-
mates.
Age at onset in LOAD was strongly influenced by the
number of APOE ε4 alleles in this study, and decreased by
about three years for every APOE ε4 allele the patient car-
ried. The decrease in age at onset of AD in carriers of the
APOE ε4 allele is well known [12,13], though the magni-
tude of the decrease in onset varies. A Finnish study found
that age at onset decreased from 76 to 69 years in LOAD
as the number of APOE ε4 alleles increased from 0 to 2
[32], whereas a twin study from Norway demonstrated no
effect on age at onset of the APOE ε4 allele, probably due
to the small number of patients included [17].
Occurrence of the APOE ε4 allele did not influence age at
onset in patients with EOAD in the present study. Similar
results are reported from another study with a larger sam-
ple size [29]. The occurrence of the APOE ε2 allele in con-
trol individuals in the present study was 11.3%, while the
frequency in AD patients was 7.3%. Both of these APOE
ε2 frequencies are increased compared to frequencies
described in a meta-analysis [25], where the frequency for
control individuals was 8.4% and for patients 3.9%. The
increased APOE ε2 frequency may be a characteristic
unique to this Norwegian population, as previous popu-
lations may have been too small to observe this increase
[15,17].
How the APOE ε4 allele exerts its influence is not fully
understood, and the magnitude of the influence is also
disputed. In the Framingham study [33] an increased risk
for AD was found both in homozygous and heterozygous
carriers of the APOE ε4 allele. However, most APOE ε4-
carriers in the Framingham study did not develop AD. The
authors emphasized that around half of all AD cases is not
caused by APOE ε4. Others consider the APOE ε4 allele to
be responsible for as much as 95% of the AD cases in
North America [34]. However, not all patients with AD
carry an APOE ε4 allele, and not all carriers of the APOE
ε4 allele develop AD [35]. In the present study 35.9% of
AD patients had no APOE ε4 allele, and 26.4% of the con-
trol population carried one or two APOE ε4 alleles. This
confirms that the APOE ε4 allele is neither necessary nor
sufficient for developing AD.
The incidence of AD increases by increasing age [36]. In
our study, analysis of the interaction of APOE ε4 by age
indicated that the effect of the APOE ε4 allele was weaker
with increasing age. The frequency of the APOE ε4 allele
decreased after 80 years in AD patients while the fre-
quency of the APOE ε2 allele increased. This suggests that
Cumulative proportion of diseased patientsFigure 1
Cumulative proportion of diseased patients.Page 5 of 7
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is likely due to genetic or environmental factors other
than the APOE ε4 [36,37]. Consequently, factors influenc-
ing the risk of AD in this age group may be interesting for
further studies.
The APOE ε4 allele is the only known genetic risk factor
for LOAD. The present study demonstrates that also in
this Norwegian population the APOE ε4 allele is a strong
risk factor for dementia, similar to what is seen in other
Caucasian populations. The effect of two APOE ε4 alleles
is stronger than of one, regarding both risk and age at
onset. Because of the similarities seen with respect to
genetic risk of APOE ε4 in this Norwegian and other Cau-
casian populations and with the likely increased genetic
homogeneity due to population demographics, this Nor-
wegian population may serve as an ideal population to
search for additional genetic risk factors contributing to
risk of developing of AD.
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